Travere Therapeutics (TVTX) Assets Average (2011 - 2026)

Travere Therapeutics (TVTX) has 16 years of Assets Average data on file, last reported at $580.2 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 1.53% year-over-year to $580.2 million; the trailing twelve-month figure through Mar 2026 stood at $580.2 million (up 1.53% YoY), and the FY2025 full-year result was $599.7 million, down 13.28% from the prior year.
• Assets Average for Q1 2026 stood at $580.2 million, up from $571.9 million in the prior quarter.
• Across five years, Assets Average topped out at $810.9 million in Q4 2023 and bottomed at $527.8 million in Q3 2024.
• The 5-year median for Assets Average is $699.4 million (2022), against an average of $670.6 million.
• The widest annual swing landed in 2022, when Assets Average increased 17.03%; it then sank 32.74% in 2024.
• A 5-year view of Assets Average shows it stood at $699.4 million in 2022, then advanced by 15.94% to $810.9 million in 2023, then tumbled by 32.26% to $549.3 million in 2024, then climbed by 4.12% to $571.9 million in 2025, then grew by 1.45% to $580.2 million in 2026.
• The last three Assets Average figures came in at $580.2 million (Q1 2026), $571.9 million (Q4 2025), and $546.9 million (Q3 2025), per Business Quant data.

Peer Comparison